arginine has been researched along with rivaroxaban in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 20 (76.92) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Bakhos, M; Hoppensteadt, D; Iqbal, O; Jeske, WP; Maddineni, J; Messmore, HL; Prechel, M; Walenga, JM | 1 |
| Jiang, X; Wong, PC | 1 |
| Ageno, W; Streif, W | 1 |
| Azuma, S; Lum, CJ | 1 |
| Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Cuker, A; Siegal, D | 1 |
| Arachchillage, DR; Baglin, T; Besser, M; Maclean, R; van Veen, JJ | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT | 1 |
| Fanikos, J; Huisman, MV | 2 |
| Levy, JH | 1 |
| Kaatz, S; Milling, TJ | 1 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM | 1 |
| Guan, H; Liu, R; Xu, Z | 1 |
| Cornelius, CC; Cripps, MW; Gales, PE; Nakonezny, PA; Vazquez, N; Wey, JC | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Dai, G; Liu, Q; Sun, L; Wang, C | 1 |
| Wu, ZY; Yang, FQ; Yang, YY; Zhang, H | 1 |
| Bari, N; Ho, JPK; Riffat, F | 1 |
| Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S | 1 |
| Austin Szwak, J; Cirbus, K; Simone, P | 1 |
| Beyer-Westendorf, J; Brückner, L; Pietsch, J; Tiebel, O | 1 |
12 review(s) available for arginine and rivaroxaban
| Article | Year |
|---|---|
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Monitoring and reversal of direct oral anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time | 2015 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2016 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban | 2016 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative | 2016 |
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Topics: Animals; Antidotes; Arginine; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles | 2016 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
[State of the art: Direct oral anticoagulants and transfusion].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia | 2017 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
1 trial(s) available for arginine and rivaroxaban
| Article | Year |
|---|---|
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
13 other study(ies) available for arginine and rivaroxaban
| Article | Year |
|---|---|
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Topics: Analysis of Variance; Anticoagulants; Antithrombin III; Arginine; Autoantibodies; Enoxaparin; Flow Cytometry; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pipecolic Acids; Platelet Activation; Platelet Aggregation; Platelet Factor 4; Polysaccharides; Rivaroxaban; Sulfonamides; Thiophenes; Thrombocytopenia | 2008 |
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time | 2014 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pipecolic Acids; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Sulfonamides; Venous Thrombosis | 2016 |
Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry.
Topics: Anticoagulants; Arginine; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Pipecolic Acids; Rivaroxaban; Sulfonamides; Tandem Mass Spectrometry; Thrombin | 2017 |
In vitro effects of a kaolin-coated hemostatic dressing on anticoagulated blood.
Topics: Adult; Anticoagulants; Antithrombins; Arginine; Bandages; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemostatics; Heparin; Humans; Kaolin; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban; Sulfonamides; Viscoelastic Substances; Vitamin K | 2018 |
Application of thrombelastography in primary total knee and total hip replacement: a prospective 87 patients study.
Topics: Anticoagulants; Arginine; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Perioperative Care; Pipecolic Acids; Postoperative Care; Preoperative Care; Prospective Studies; Prothrombin Time; Pulmonary Embolism; Rivaroxaban; Sulfonamides; Thrombelastography; Thrombophilia; Venous Thrombosis | 2019 |
An online dual-enzyme co-immobilized microreactor based on capillary electrophoresis for enzyme kinetics assays and screening of dual-target inhibitors against thrombin and factor Xa.
Topics: Arginine; Catechin; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Electrophoresis, Capillary; Enzyme Activation; Enzyme Assays; Enzyme Inhibitors; Enzymes, Immobilized; Factor Xa; Kinetics; Molecular Docking Simulation; Pipecolic Acids; Rivaroxaban; Sulfonamides; Thrombin | 2020 |
Management of epistaxis in patients on novel oral anticoagulation therapy.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index | 2020 |
Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia.
Topics: Adult; Aged; Arginine; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Sulfonamides; Thrombocytopenia | 2022 |
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arginine; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pipecolic Acids; Pyridones; Rivaroxaban; Sulfonamides; Tandem Mass Spectrometry; Thrombin | 2022 |